Armel F. Setubi

Dr. Armel F. Setubi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Children and Youth Services Review
Verified
Journal Article
Open access
AKAnjalee Kohli
Anjalee Kohli
BSBryan Shaw
Bryan Shaw
JGJamie Greenberg
Jamie Greenberg
EDErin DeGraw
Erin DeGraw
LHLameck Habumugisha
Lameck Habumugisha
CYChristina Yantis
Christina Yantis

17 March 2022 in Iberoamerican Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASArmel F. Setubi
Armel F. Setubi
ENEsther Nakoya
Esther Nakoya
ATAnnie-Flore K. Tchougene
Annie-Flore K. Tchougene
XFXavier-Gabriel Fopokam
Xavier-Gabriel Fopokam
Introduction: SARS-CoV-2 continues to raise health and socio-economical concerns globally. The recent discovery of the B.1.1.529 (Omicron) variant with its critical mutations has heightened the debate about the need for a better global vaccination rollout to prevent the emergence of new SARS-CoV-2 strains. Optimizing vaccine rollout in Africa is crucial for the management of the pandemic and preventing the rise of new strains. To better direct efforts and interventions it is important to know what parts of the continent necessitate more attention. Material and Methods: 30 African countries were grouped in five geographical subregions, six countries for each subregion. Data on confirmed cases, doses administered, fully vaccinated, and deaths were extracted from the Johns Hopkins Coronavirus Resource Center database. The ANOVA test evaluated differences in means for these variables classified by subregions. The correlation test and the linear regression examined the relationship between these independent variables and total deaths. Results: There was a significant regional difference in confirmed cases (P<0.0001), and in fully vaccinated (P=0.01) across the five subregions. The overall model showed that there is a significant regional difference in the three variables’ effect on total deaths (P<0.0001). The linear regression indicated an association between the total number of deaths in relation to the confirmed cases, doses administered, and fully vaccinated (P<0.0001). Discussion: This study indicates that a relation exists between total deaths and the variables confirmed cases, doses administered, and fully vaccinated. More importantly, African countries grouped in geographical subregions perform differently in terms of vaccine rollout, and that offers insights for better and oriented interventions.

6 August 2020 in Iberoamerican Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASArmel F. Setubi
Armel F. Setubi
MWMersha Wubie
Mersha Wubie
ADAlain Pitti Djida
Alain Pitti Djida
XFXavier Emmanuel Fosoumo
Xavier Emmanuel Fosoumo
BNBasile Tchiotchoua Nousse
Basile Tchiotchoua Nousse
ATAnnie-Flore Kwangwa Tchougene
Annie-Flore Kwangwa Tchougene
Iberoam J Med, vol.2, n4, p.279-284, 2020

26 October 2025 in Discover Public Health
Verified
Journal Article
Open access
PDF file
ASArmel F. Setubi
Armel F. Setubi
ABAngela Barr
Angela Barr
ZTZoumana I. Traore
Zoumana I. Traore
BHBarnabé Hounguevou
Barnabé Hounguevou
AAAugustina O. Amadu
Augustina O. Amadu
CHChristian J. Hunter
Christian J. Hunter
This study aimed to identify the factors influencing the use of electronic pillboxes in Africa and to outline their implications for practice and policy. A

10 July 2026 in Bulletin of the National Research Centre
Verified
Journal Article
Open access
PDF file
ASArmel F. Setubi
Armel F. Setubi
BSBryan Shaw
Bryan Shaw
KRKatherine Robsky
Katherine Robsky
IGIgnace Gashongore
Ignace Gashongore
MOMichael Ochieng Otieno
Michael Ochieng Otieno
CHChristian J. Hunter
Christian J. Hunter
Background: Maintaining high levels of medication adherence is essential for the success of antiretroviral therapy (ART), yet non-adherence remains a persistent challenge in resource-limited settings. Smart Pillboxes (SPBs) offer a promising digital solution by providing real-time adherence monitoring and clinical decision support. However, the successful implementation of these tools among people living with HIV (PLHIV) depends on understanding user-level barriers. This study examines the sociodemographic, behavioral, and infrastructural factors that influence the willingness to adopt SPBs among people living with HIV in Cameroon. Methods: This cross-sectional study involved 153 PLHIV recruited from clinical sites in the Center Region of Cameroon. The Diffusion of Innovations (DOI) framework informed the conceptual categorization. Due to convergence issues with log-binomial models, statistical analyses utilized multivariable modified Poisson regressions with robust standard errors to identify predictors of adoption intent. Global model significance was assessed via the Wald Chi-square test. A bootstrap procedure was applied to validate the stability of identified predictors. Results: At the outset, 60.8% of participants self-classified as adopters. Females were the majority (53%), and over half of the participants were single (55.6%). The final multivariable model demonstrated high statistical significance (Wald $$\:{\chi\:}^{2}$$ = 29.5, p = 0.0019). Higher educational attainment (MA; aRR = 1.64, p = 0.004) and frequent medication forgetfulness (aRR = 1.35, p = 0.026) were identified as robust facilitators of adoption willingness. Adoption intent was significantly attenuated by the use of phone reminders (aRR = 0.77, p = 0.049) and unemployment (aRR = 0.64, p = 0.049). Conclusion: Adoption intent of SPBs is driven by a synergy of socioeconomic status and felt behavioral needs. While infrastructure is a necessary baseline, educational attainment and perceived utility are the primary determinants of adoption intent in this urban population.

15 November 2026 in Viruses
Verified
Journal Article
Open access
PDF file
ASArmel F. Setubi
Armel F. Setubi
DMDiana Mukuku
Diana Mukuku
VKVinie Kouamou
Vinie Kouamou
Most studies on the HIV reservoir have focused on resting memory CD4+ T cells. This focus has shaped how researchers think about viral persistence and has guided the development of “shock-and-kill” strategies. But new research shows the reservoir is much broader. It includes myeloid, stromal, and non-immune cells, each with its own ways of maintaining viral latency. Macrophages, microglia, and dendritic cells can carry replication-competent HIV. Different epigenetic mechanisms and transcription factors regulate their proviruses, highlighting the need to determine whether cure strategies designed primarily for T cells can also address these reservoirs. The reservoir is also shaped by its location in the body. The brain, gut, and liver each create different challenges for persistence and treatment, challenges that cannot be explained just by cell type. We argue that the HIV reservoir is not a single entity. Instead, it is a collection of unique latency programs in different cells and tissues. Ignoring this complexity is a major gap in current cure research. To make progress, we need to map the reservoir’s true distribution, use the right assays for each cell type, and design drugs and therapies that match this diversity.